香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 中國醫療器械有限公司截至 2025 年 9 月 30 日止九個月之未經審核財務報表 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 茲載列國藥控股股份有限公司旗下一間附屬公司，中國醫療器械有限公司（「國藥器械」）於 2025 年 10 月 23 日於中國貨幣網及上海清算所網站刊發的截至 2025 年 9 月 30 日止九個月之本 部及合併的未經審核資產負債表、利潤表及現金流量表，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 10 月 23 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Gr ...

Core Viewpoint - Morgan Stanley believes that the stock price of China National Pharmaceutical Group (01099) will rise within the next 30 days, with a probability of 70% to 80%, and has given it an "Overweight" rating with a target price of HKD 22.5 [1] Group 1: Company Performance - Two subsidiaries of China National Pharmaceutical Group have reported third-quarter results showing a positive trend quarter-on-quarter, which is expected to have a beneficial effect on the group [1] - China National Pharmaceutical Co., Ltd. (600511.SH), a major distributor in Beijing and a key supplier of anesthetics, reported a year-on-year revenue and profit increase of 4% and 13% respectively in the third quarter, indicating a positive turnaround [1] - China National Pharmaceutical Group's southern distribution network and Guoda Pharmacy chain, represented by China National Pharmaceutical Group Co., Ltd. (000028.SZ), saw a year-on-year decline in revenue and net profit of 2% and 10% respectively in the third quarter, but the company noted that its distribution business has "stabilized and is recovering growth" [1] Group 2: Market Conditions - The pharmaceutical distributor sector is currently not receiving much market attention due to weak domestic demand and the impact of technology licensing activities in China, which is expected to persist into 2025 [1] - The current valuation of China National Pharmaceutical Group is considered a good entry point, with a projected price-to-earnings ratio of 6.5 times for 2026 [1]

Core Viewpoint - Morgan Stanley believes that the stock price of China National Pharmaceutical Group (01099) will rise within the next 30 days, with a probability of 70% to 80%, and has given a "Buy" rating with a target price of HKD 22.5 [1] Group 1: Company Performance - Two subsidiaries of China National Pharmaceutical Group have reported third-quarter results showing a positive trend, which is expected to have a beneficial effect on the group [1] - China National Pharmaceutical Co., Ltd. (600511.SH), a major distributor in Beijing and a key supplier of anesthetic drugs, reported a year-on-year revenue and profit increase of 4% and 13% respectively in the third quarter, indicating a positive turnaround [1] - China National Pharmaceutical Group's southern distribution network and Guoda Pharmacy chain, represented by China National Pharmaceutical Holdings (000028.SZ), experienced a year-on-year revenue and net profit decline of 2% and 10% respectively in the third quarter, but the company noted that its distribution business has "stabilized and is recovering growth" [1] Group 2: Market Outlook - The pharmaceutical distributor is expected to remain under market attention until 2025 due to weak domestic demand and the impact of technology licensing activities in China [1] - Based on a projected price-to-earnings ratio of 6.5 times for 2026, Morgan Stanley considers that China National Pharmaceutical Group currently presents a good entry opportunity [1]

Core Viewpoint - Morgan Stanley reports a 70% to 80% probability that the stock price of China National Pharmaceutical Group (Sinopharm) will rise in the next 30 days, assigning an "Overweight" rating and a target price of HKD 22.5 [1] Financial Performance - Sinopharm's subsidiary, Sinopharm Holdings, reported a year-on-year revenue and profit increase of 4% and 13% respectively for Q3, indicating a positive turnaround [1] - Another subsidiary, Sinopharm United, experienced a year-on-year decline in revenue and net profit of 2% and 10% respectively for Q3, but noted that its distribution business has stabilized and is recovering [1] Market Outlook - Morgan Stanley indicates that pharmaceutical distributors will remain under market scrutiny until 2025 due to weak domestic demand and the impact of technology licensing activities in China [1] - The current entry point for Sinopharm is considered favorable, with a projected price-to-earnings ratio of 6.5 times for 2026 [1]

Group 1 - The core point of the article is that China National Pharmaceutical Group (国药控股) shares have increased by over 3%, currently trading at HKD 19.33 with a transaction volume of HKD 71.91 million [1] - The company will hold a board meeting on October 24 to consider and approve the unaudited quarterly results for the nine months ending September 30, 2025 [1] - China National Pharmaceutical's subsidiary, China National Pharmaceutical Co., reported a third-quarter revenue of RMB 13.747 billion, representing a year-on-year growth of 3.58% [1] Group 2 - The net profit attributable to shareholders for the subsidiary in the third quarter was RMB 544 million, showing a year-on-year increase of 13.10% [1]

Core Viewpoint - China National Pharmaceutical Group (国药控股) shares increased by over 3%, reaching a price of HKD 19.33 with a trading volume of HKD 71.91 million [2] Company Summary - The stock price of China National Pharmaceutical Group rose by 3.26% [2] - The current share price is HKD 19.33 [2] - The trading volume at the time of reporting was HKD 71.91 million [2]

Core Viewpoint - China National Pharmaceutical Group (国药控股) shares rose over 3%, currently trading at HKD 19.33 with a transaction volume of HKD 71.91 million [1] Company Performance - China National Pharmaceutical Group will hold a board meeting on October 24 to consider and approve the unaudited quarterly results for the nine months ending September 30, 2025 [1] - Its subsidiary, China National Pharmaceutical Co., reported a third-quarter revenue of RMB 13.747 billion, representing a year-on-year increase of 3.58% [1] - The net profit attributable to shareholders for the same period was RMB 544 million, showing a year-on-year growth of 13.10% [1]

智通财经APP讯，国药控股(01099)公布附属国药股份(600511.SH)2025年前三季度业绩，公司前三季度 实现营收393.81亿元，同比增长3.56%;归属于上市公司股东的净利润14.92亿元，同比增长0.74%;扣非净 利润14.7亿元，同比下降1.27%;基本每股收益1.9778元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確性或完 整性亦不發表任何聲明,並明確表示,概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 ( 於中華人民共和國註冊成立之股份有限公司 , 在香港以國控股份有限公司之名稱經營業務 ) (股份代號 :01099) 公告 國藥股份 2025年第三季度之 主要未經審核會計數據和財務指標 本公告乃根據香港聯合交易所有限公司證券上市規則第13.09條及證券及期貨條例(香港法 例第 571 章)第 XIVA 部刊發。 茲提述國藥控股股份有限公司(「本公司」)於2025年10月21日刊發之海外監管公告(「該 公告」),內容有關本公司附屬公司國藥集團藥業股份有限公司(「國藥股份」,其 A 股於上 海證券交易所上市(股票代碼：600511))之 2025 年第三季度報告。 國藥股份之主要未經審核會計數據和財務指標 單位:元 幣種:人民幣 本公司董事會謹此提醒股東及公眾投資者注意以下於該公告內載列之國藥股份 2025 年第 三季度之主要未經審核會計數據和財務指標。 * 本公司以其中文名稱及英文名稱「 Sinoph ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示,概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 ( 於中華人民共和國註冊成立之股份有限公司 , 在香港以國控股份有限公司之名稱經營業務 ) (股份代號 :01099) 海外監管公告 國藥集團藥業股份有限公司 2025 年第三季度報告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列國藥控股股份有限公司旗下一間 A 股於上海證券交易所上市的附屬公司，國 藥集團藥業股份有限公司,於 2025 年 10 月 21 日於上海證券交易所網站刊發的《國藥 集團藥業股份有限公司 2025 年第三季度報告》，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先 生、祖敬先生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李 培育先生、吳德龍先生、俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinoph ...